Arca
Skip to content
Tools
Tools

Bevacizumab 2.5 mg/0.1 mL

Recall D-0531-2023, part of FDA recall event 91972. See Pine Pharmaceuticals's company page.

Pine Pharmaceuticals, LLC started this Class III drug recall on Mar 27, 2023 (voluntary: firm initiated); FDA lists it as terminated, terminated Jun 1, 2023.

  • Classification: Class III
  • Started: Mar 27, 2023
  • Status: Terminated

Why It Was Recalled

Class III

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Record

Product
Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1
Quantity
932 syringes
Lots and codes
Lot # 66377, Exp. Date: 06/28/2023. Syringe may be labeled incorrectly as lot# 66316
Distribution
Nationwide in the USA
Recalling firm
Pine Pharmaceuticals, LLC, Tonawanda, NY, United States
How the firm notified
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
FDA classified
Apr 13, 2023

Pine Pharmaceuticals, LLC's Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.